stockrowHalozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.
- Revenue
- +39.2%
- EPS
- +45.6%
- Free cash flow
- −58.6%
- Total debt
- +115.1%
Quarter to September 2026, against a year earlier
Follow HALO
Alert me
Halozyme Therapeutics, Inc. (HALO) Free cash flow
Halozyme Therapeutics, Inc.'s free cash flow for fiscal 2025 was $644.6M, up 37.6% from $468.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was $898.3M. Over the past ten years it has ranged from −$89.5M (fiscal 2019) to $644.6M (fiscal 2025) — the current reading is the highest in ten years. Free cash flow has risen for 3 consecutive fiscal years. Halozyme Therapeutics, Inc. ranks 7th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $644.6M | 37.62% |
| FY2024 | $468.4M | 25.47% |
| FY2023 | $373.3M | 42.85% |
| FY2022 | $261.3M | (12.31%) |
| FY2021 | $298.0M | 451.55% |
| FY2020 | $54.0M | — |
| FY2019 | −$89.5M | — |
| FY2018 | −$54.2M | — |
| FY2017 | $132.7M | — |
| FY2016 | −$53.5M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $258.3M | 9.10% |
| Jun 2026 | $236.7M | 34.24% |
| Mar 2026 | $176.3M | — |
| Dec 2025 | −$231.3M | — |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| EXEL Exelixis, Inc. compare | $1.1B |
| HALO Halozyme Therapeutics, Inc. | $898.3M |
| JAZZ Jazz Pharmaceuticals PLC compare | $664.5M |
| BMRN BioMarin Pharmaceutical Inc. compare | $557.9M |
| ASND Ascendis Pharma A/S compare | $387.5M |
| TECH Bio-Techne Corp compare | $263.2M |
| KYMR Kymera Therapeutics, Inc. compare | −$288.9M |
| BBIO BridgeBio Pharma, Inc. compare | −$369.8M |
| SMMT Summit Therapeutics PLC compare | −$459.8M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on HALO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement